Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
1.84 ^USD	-35.21%		-23.97%	-97.10%

26/06	Top Midday Decliners	MT
26/06	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	27/06	MT
Sector Update: Health Care Stocks Advance Late Afternoon	11/06	MT
CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall	10/06	MT
CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week	03/06	MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	30/01	MT
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	17/01	CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	18/12	CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	22/11	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland	11/23/11	CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme	07/23/07	CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy	14/23/14	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme	03/23/03	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
CNS Pharmaceuticals, Inc. Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm with First Patient Enrolled in Switzerland	09/23/09	CI
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug	25/23/25	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Highlights

Filters